In recent studies, AMITIZA (tm)(lubiprostone) demonstrated improvements in relief of symptoms associated with irritable bowel syndrome with constipation (IBS-C), such as abdominal bloating and ...
AMITIZA(TM) (lubiprostone), the first selective chloride channel activator for the treatment of chronic idiopathic constipation, was effective and well-tolerated in treating the symptoms of chronic ...
BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration ...
Please provide your email address to receive an email when new articles are posted on . Kessoku and colleagues enrolled 150 patients with NAFLD in the randomized control trial. Patients received 12 g ...
There are additional requirements and commitments needed for MNK's supplemental NDA for Amitiza. Delays in approval remove a near-term catalyst for MNK. The company's remaining R&D efforts appear ...
BETHESDA, Md., May 11, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that it entered into an exclusive license, ...
The Safety Profiles of Novel Agents Are Likely to be Scrutinized by Both Clinicians and Payers, According to a New Report from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision ...
WASHINGTON The Food and Drug Administration’s Center for Drug Evaluation and Research has approved a labeling change to Sucampo Pharmaceuticals chronic idiopathic constipation drug Amitiza. The new ...
<0> Sucampo Pharmaceuticals, Inc.Silvia Taylor, 1-240-223-3718orKate de Santis, 1-240-223-3834orTakeda Pharmaceuticals U.S.A., Inc.Jocelyn Gerst, 1-224-554-5542 </0 ...
Sucampo and Takeda Pharmaceuticals announced that the FDA has granted priority review of their supplemental new drug application (sNDA) filing for Amitiza (lubiprostone), seeking approval for the ...
The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note ...
The Food and Drug Administration on Tuesday approved the first U.S. drug to treat irritable bowel syndrome with constipation in adult women, a medicine marketed by Takeda Pharmaceutical Co and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback